Iovance Biotherapeutics IOVA shares are trading higher after the company announced Lifileucel achieved an 86% response rate in a melanoma trial.
Iovance Biotherapeutics' stock is trading up 16.35% to a price of $18.79. Thursday the stock has been traded at a volume of 30.71 million, about 990.27% of its recent 30-day volume average of 3.10 million.
The stock's 50-day moving average was $30.25 at the time this article was published. Over the past fifty-two weeks, the price has risen as high as $54.21 and fallen to a low of $15.88.
Benzinga Pro provides investors with timely and accurate explanations of why a stock is moving. Subscribe to receive real-time alerts explaining stock price movements. Click here to learn more.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.